The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View lym content recommended for you

EHA 2024 abstracts: What’s hot in lymphoma and CLL?

By Abhilasha Verma

Jun 10, 2024

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL.

Indolent and mantle cell NHL

LB3439	Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3, double-blind, placebo-controlled ECHO trial
S231	Glofitamab monotherapy in patients with heavily pretreated relapsed or refractory mantle cell lymphoma: updated analysis from a phase I/II study
S232	Primary analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed/refractory follicular lymphoma
S233	Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated R/R FL after ≥3 years of follow-up: subgroup analysis of a pivotal phase II study
S234	Epcoritamab induces deep responses in relapsed or refractory (R/R) follicular lymphoma (FL): safety and pooled efficacy data from EPCORE NHL‑1 pivotal and cycle (C) 1 optimization (OPT) FL cohorts
P1138	Preliminary safety and efficacy of BOVEN (zanubrutinib , obinutuzumab , and venetoclax ) for frontline therapy for older patients with mantle cell lymphoma
P1146	Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance therapy in FL: novel results from EPCORE NHL‑2 arms 6 and 7

Hodgkin lymphoma

S225	The randomized study GHSG HD21 shows superior tolerability and efficacy of BRECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma
S226	EORTC-1537-COBRA: very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study.
S244	An abbreviated course of A+AVD followed by nivolumab consolidation for frontline therapy in patients with limited stage Hodgkin lymphoma
P1084	Long-term cause-specific mortality in a cohort of 1,435 Hodgkin lymphomas treated at the national adult public cancer program in Chile over a 30-year period
P1093	Brentuximab vedotin - ESHAP significantly increases the metabolic complete remission rate versus ESHAP in relapsed classical Hodgkin lymphoma. Final results of the BRESELIBET prospective trial
P2041	Brentuximab vedotin and bendamustine for relapsed Hodgkin lymphoma: high CMR rate and manageable toxicity

T-cell lymphoma

LB3442	ELA026 targeting of SIRP(+) immune cells results in a high response rate and improved 2-month survival of treatment-naive malignancy-associated hemophagocytic lymphohistiocytosis in a phase 1 study
S245	Outcomes of autologous and allogeneic stem cell transplantation for T-cell lymphoma: an updated analysis of the EBMT lymphoma working party
S247	Valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: efficacy by prior lines of treatment and last treatment outcome from the VALENTINE-PTCL01 study
P2106	Chidamide with azacitidine and CHOP treatment plus auto-ASCT for patients with newly diagnosed peripheral T-cell lymphoma: interim analysis of a prospective, single center , single-arm, phase 2 trial

Aggressive B-NHL

LB3438	Glofitamab plus gemcitabine and oxaliplatin (GLOFIT-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO)
S236	Feasibility and clinical efficacy of atezolizumab consolidation in high risk diffuse large B-cell lymphoma: final analysis of the HOVON 151
S237	Englumafusp alfa (CD19/4-1BBL) combined with glofitamab is safe and shows high efficacy in patients with R/R aggressive B-NHL: final results of the dose-escalation part of phase1 trial BP41072
S238	Biomarker-adapted treatment in high-risk large B-cell lymphoma: long-term follow-up of a NORDIC phase II trial
S239	First data from subcutaneous epcoritamab+polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CHP) for first-line diffuse large B-cell lymphoma (DLBCL): EPCORE NHL-5
S241	TRANSCAR: A real-life outcome study of relapsed/refractory transformed indolent non-Hodgkin lymphoma in the context of CAR T-cells a DESCART analysis
S272	Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by ASCT as second-line treatment in patients with R/R large B-cell lymphoma: 3-year follow-up of TRANSFORM
P2086	Efficacy and safety of zanubrutinib combined with R-CHOP regimen in the treatment of newly diagnosed diffuse large b-cell lymphoma with extranodal involvement: a prospective phase II trial in China
P2091	A phase II, single-arm, open-label study to evaluate the safety and efficacy of tafasitamab combined with lenalidomide in patients with relapsed/ refractory diffuse large B-cell lymphoma
P2110	Bruton tyrosine kinase inhibitors and chidamide -combined therapy in relapsed or refractory diffuse large B-cell lymphoma

Chronic lymphocytic leukemia (CLL)

S155	Latest results from an ongoing first-in-human phase 1a/b study of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory CLL and other B-cell malignancies
S156	Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (SONRO) in combination with zanubrutinib (ZANU) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses
S157	Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study
S158	Characteristics associated with response to lisocabtagene maraleucel (liso‑cel) in patients (pts) with R/R CLL/SLL: exploratory analyses from TRANSCEND CLL 004
S160	Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17P) and/or TP53 : preliminary results from SEQUOIA arm D
S161	Minimal residual disease-guided combination of ibrutinib plus venetoclax compared to FCR in untreated patients with CLL of intermediate risk : interim results from the phase II FILO trial.
S162	7-year update on a phase 2 trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL
S163	Single-agent epcoritamab leads to deep responses in patients (pts) with Richter’s transformation (RT): primary results from the EPCORE CLL-1 trial
S164	Combined pirtobrutinib, venetoclax, and obinutuzumab in first-line treatment of patients with chronic lymphocytic leukemia (CLL): a phase 2 trial
P699	6-year time to next treatment (TTNT) extrapolation curve for GLOW study: first-line ibrutinib + venetoclax (I+V) offers long treatment-free period for elderly/unfit CLL patients
P1841	A phase II study of time-limited treatment with acalabrutinib plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia
P1839	Updated results of combination treatment with ibrutinib and venetoclax in patients with chronic lymphocytic leukemia and complex karyotype: 4-year follow-up

EHA 2024 top abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2024

Subscribe to get the best content delivered to your inbox